Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ drug therapy
Imatinib Mesylate
/ pharmacology
Humans
Oxidative Phosphorylation
/ drug effects
Animals
Neoplastic Stem Cells
/ drug effects
Mice
Cell Line, Tumor
Thiophenes
/ pharmacology
Xenograft Model Antitumor Assays
Antineoplastic Agents
/ pharmacology
Cell Proliferation
/ drug effects
Drug Synergism
Protein Kinase Inhibitors
/ pharmacology
chronic myeloid leukemia
oxidative phosphorylation
stem cell
thiophene carboxamide
tyrosine kinase
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
15 Oct 2024
15 Oct 2024
Historique:
received:
04
10
2024
revised:
10
10
2024
accepted:
13
10
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
26
10
2024
Statut:
epublish
Résumé
Patients with chronic myeloid leukemia (CML) respond to tyrosine kinase inhibitors (TKIs); however, CML leukemic stem cells (LSCs) exhibit BCR::ABL kinase-independent growth and are insensitive to TKIs, leading to disease relapse. To prevent this, new therapies targeting CML-LSCs are needed. Rates of mitochondria-mediated oxidative phosphorylation (OXPHOS) in CD34
Identifiants
pubmed: 39456874
pii: ijms252011093
doi: 10.3390/ijms252011093
pii:
doi:
Substances chimiques
Imatinib Mesylate
8A1O1M485B
Thiophenes
0
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Bristol-Myers-Squibb
ID : NA
Organisme : Pfizer
ID : NA
Organisme : Ohara Pharmaceuticals
ID : NA